KR101781083B1 - Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis - Google Patents
Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis Download PDFInfo
- Publication number
- KR101781083B1 KR101781083B1 KR1020170007857A KR20170007857A KR101781083B1 KR 101781083 B1 KR101781083 B1 KR 101781083B1 KR 1020170007857 A KR1020170007857 A KR 1020170007857A KR 20170007857 A KR20170007857 A KR 20170007857A KR 101781083 B1 KR101781083 B1 KR 101781083B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- sepsis
- dimethoxychromone
- hydroxy
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 111
- 241000047339 Salicornia brachystachya Species 0.000 title claims description 4
- 206010040047 Sepsis Diseases 0.000 title abstract description 49
- 208000035868 Vascular inflammations Diseases 0.000 title abstract description 27
- 239000000203 mixture Substances 0.000 title abstract description 22
- 102100037907 High mobility group protein B1 Human genes 0.000 claims abstract description 29
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims abstract description 29
- 230000036541 health Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- ANCHXLMTFNOVDK-UHFFFAOYSA-N 7-hydroxy-6,8-dimethoxychromen-4-one Chemical compound COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 29
- AVEFEKKVKSUABY-UHFFFAOYSA-N 6,7-dimethoxychromen-4-one Chemical compound O1C=CC(=O)C2=C1C=C(OC)C(OC)=C2 AVEFEKKVKSUABY-UHFFFAOYSA-N 0.000 claims description 22
- 244000269722 Thea sinensis Species 0.000 claims description 18
- 229940094952 green tea extract Drugs 0.000 claims description 18
- 235000020688 green tea extract Nutrition 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 229940125898 compound 5 Drugs 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- BFRVCQPRUJFVFU-UHFFFAOYSA-N 6-methoxy-3,4-dihydrochromen-2-one Chemical compound O1C(=O)CCC2=CC(OC)=CC=C21 BFRVCQPRUJFVFU-UHFFFAOYSA-N 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 abstract description 25
- 229930003949 flavanone Natural products 0.000 abstract description 22
- 235000011981 flavanones Nutrition 0.000 abstract description 22
- 150000002208 flavanones Chemical class 0.000 abstract description 12
- 150000004777 chromones Chemical class 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 229940125904 compound 1 Drugs 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 229940125782 compound 2 Drugs 0.000 description 19
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 235000009569 green tea Nutrition 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
- 210000003989 endothelium vascular Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- CFAXKRNPHJYYNQ-UHFFFAOYSA-N 9-hydroxy-6-(2-hydroxyphenyl)-6,7-dihydro-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound OC1=CC=CC=C1C1OC2=CC(OCO3)=C3C(O)=C2C(=O)C1 CFAXKRNPHJYYNQ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004534 cecum Anatomy 0.000 description 7
- -1 chromone derivative compounds Chemical class 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 6
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 6
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229960003699 evans blue Drugs 0.000 description 5
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000005167 vascular cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700010013 HMGB1 Proteins 0.000 description 3
- 102000055207 HMGB1 Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000003817 vacuum liquid chromatography Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DUQBEQWUJYJCGB-UHFFFAOYSA-N C1=CC=C2OC(=O)C(OCC)CC2=C1 Chemical compound C1=CC=C2OC(=O)C(OCC)CC2=C1 DUQBEQWUJYJCGB-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000201895 Salicornia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940056176 drotrecogin alfa Drugs 0.000 description 1
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000020765 fenugreek extract Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940084362 forane Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 함초 유래의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물에 관한 것으로서, 상기 화합물은 플라바논 또는 크로몬 유도체(flavanones or chromones derivatives)로서, 상기 화합물은 HMGB1(high mobility group box 1)의 발현을 억제하고, CLP 수술법(cecal ligation and puncture operation)에 따른 마우스의 사망률을 억제하는 효과가 우수하여 혈관 염증 또는 패혈증의 예방 또는 치료용 의약 조성물이나 혈관 염증 또는 패혈증의 예방 또는 개선용 건강기능식품으로 용이하게 이용가능하다. The present invention relates to a composition for preventing or treating vascular inflammation or sepsis comprising a compound derived from Hamcho, wherein the compound is flavanones or chromone derivatives, wherein the compound is HMGB1 (high mobility group box 1) and inhibits the mortality of mice according to the CLP procedure (cecal ligation and puncture operation), thereby preventing or treating vascular inflammation or sepsis or preventing or improving vascular inflammation or sepsis It is easily available as a health functional food.
Description
본 발명은 함초로부터 분리된 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating vascular inflammation or sepsis which contains a compound isolated from green tea.
혈관내피는 혈관운동긴장(vasomotor tone), 혈액의 수송, 지혈 안정, 증식, 생존, 선천성 또는 적응성 면역 등을 포함하는 다양한 생리학적 기능에 대해 중요한 역할을 하고 있다. 따라서, 혈관내피의 기능장애는 생리학적인 반응이상을 초래하는데, 주로, 급성적인 폐손상, 아나필락시스(anaphylaxis), 동맥경화증, 패혈증과 같은 다양한 혈관 염증 증상으로부터 유도된다(Pharmacological Reports. 2008, 60, 139-143; Crirculation. 2007, 115, 1285-1295; Journal of Cellular Physiology. 2014, 229, 620-630).The vascular endothelium plays an important role in a variety of physiological functions including vasomotor tone, blood transport, hemostasis, proliferation, survival, congenital or adaptive immunity, and the like. Thus, vascular endothelial dysfunction results in physiological response abnormalities, which are mainly induced from a variety of vascular inflammatory conditions such as acute lung injury, anaphylaxis, atherosclerosis, sepsis (Pharmacological Reports. 2008, 60 Journal of Cellular Physiology, 2014, 229, 620-630).
패혈증(sepsis, 敗血症)은 녹농균, 대장균, 연쇄상구균, 포도상구균, 폐렴균 같은 미생물에 감염되었을 때 미생물이나 그 미생물이 생산한 독소에 의해 오한과 함께 고열, 관절통, 두통, 권태감 등의 전신적인 증상이 나타나는 상태를 말한다. 이러한 증상이 심해지면 저혈압이 동반되고 소변량이 줄며 패혈성 쇼크가 나타나기도 한다(Nat. Med. 2003, 9, 517-524). 미생물의 감염 경로를 잘 알 수 없는 경우도 있으나 맹장염, 중이염, 피부화농증, 욕창, 폐질환, 담낭염, 신우염, 골수염 등이 패혈증의 원인 병소로 알려져 있다. 혈액검사와 소변검사, 뇌척수액 검사 등을 통해 패혈증을 진단할 수 있으며 백혈구 수와 급성염증성물질이 증가한 경우도 패혈증을 진단하는데 도움을 준다. Sepsis (sepsis) is caused by toxins produced by microorganisms or microorganisms when they are infected with microorganisms such as Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Staphylococcus aureus, and Pneumococcus, and it causes chills, systemic symptoms such as high fever, joint pain, headache, State that appears. If these symptoms are severe, hypotension is accompanied by decreased urine volume and septic shock (Nat. Med. 2003, 9, 517-524). Although the infection pathways of microorganisms are not well known, appendicitis, otitis media, skin pyrexia, pressure ulcer, lung disease, cholecystitis, pyelonephritis and osteomyelitis are known as the cause of sepsis. Blood tests, urine tests, and CSF tests can be used to diagnose sepsis. Increased leukocyte counts and acute inflammatory agents also help to diagnose sepsis.
아직까지 패혈증의 치료를 위한 근본적인 치료제는 확인되지 않은 상태이다. 패혈증은 통상적인 염증 억제 치료방법으로는 잘 낫지 않으며, 유일하게 FDA 승인을 받은 드로트레코긴 알파(drotrecogin alfa, Xigris®, Engl. J. Med. 2012, 366, 2055-2064)조차도 임상단계에서 패혈증에 대한 치료 효과가 명확하지 않아 이에 대한 연구가 중단되어 있는 실정이다. 현재 패혈증은 주로 항생제나 항진균제 주사로 치료하고, 치료 약제와 기간은 미생물의 종류에 따라 결정한다. 또 환자의 상태에 따라 혈액투석 또는 수혈을 하기도 한다. 항생제와 항진균제가 잘 들으면 패혈증은 완치되기도 하지만, 약제에 내성이 있는 미생물에 감염된 경우와 면역력이 약한 환자인 경우, 또 너무 늦게 치료를 시작한 경우 등에서는 치료가 어려워 환자가 사망하기도 한다. 또한, 패혈증의 사망률은 50~70%에 달해 매우 높은 편이며, 전세계적으로도 사망의 원인 중에서 높은 비중을 차지하는 것으로 알려져 있다(Nat. Med. 2003, 9, 517-524). 패혈증에 대한 합병증이 발생할 경우에는 후유증이 생길 수 있다. 합병증으로 뇌막염이 있는 경우에는 신경학적 후유증이, 화농성 관절염이 함께 나타났을 경우에는 뼈 성장에 이상이 생기기도 한다. Until now, the fundamental treatment for sepsis has not been confirmed yet. Sepsis is not well treated with conventional anti-inflammatory therapy and even the only FDA-approved drotrecogin alfa (Xigris ® , Engl. J. Med. 2012, 366, 2055-2064) The effect of the treatment is unclear. Currently, sepsis is treated mainly by injection of antibiotics or antifungal drugs, and the duration of the treatment is determined by the type of microorganism. Hemodialysis or transfusion may also be performed depending on the patient's condition. When antibiotics and antifungal agents are well tolerated, sepsis may be cured, but patients may die because they are difficult to treat when they are infected with a drug resistant microorganism, when their immunity is weak, or when they start treatment too late. In addition, the mortality rate of sepsis is very high, reaching 50-70%, and it is known that it accounts for a high percentage of deaths worldwide (Nat. Med. 2003, 9, 517-524). Complications associated with sepsis can lead to sequelae. Complications include meningitis, neurological sequelae, and pyogenic arthritis together with bone growth abnormalities may occur.
함초(Salicornia herbacea)의 공식적인 명칭은 퉁퉁마디이지만 주로 함초라고 불린다. 바닷물이 잘 드나들고 비교적 땅이 잘 굳는 갯벌지에서 자란다. 줄기는 육질이고 원기둥 모양이며 가지가 마주달리고 퇴화한 비늘잎이 마주달리며 마디가 불룩하게 튀어나오므로 퉁퉁마디라는 이름이 생겼다. 우리나라 서해안과 남해안 전역에 고루 분포한다. 함초는 오래전부터 식용으로도 많이 먹었는데 줄기를 잘라다가 국을 끓이거나, 갈아서 밀가루에 함께 반죽하여 전을 부쳐서 먹기도 한다. 미네랄이 풍부하기 때문에 건강식으로 알려져 있다. 함초는 몸 안에 쌓인 독소와 숙변을 없애고, 암, 자궁근종, 축농증, 고혈압, 저혈압, 요통, 당뇨병, 기관지천식, 갑상선 기능저하, 갑상선 기능항진, 피부병, 관절염, 신장염이나 갖가지 난치병에 탁월한 치료 효과를 지니고 있는 놀라운 약초라 알려져 있다. 또한 함초는 숙변을 제거하고 비만증을 치료하는 효과가 탁월하며, 혈액순환을 좋게 하고 피를 맑게 하며 혈관을 튼튼하게 하여 염증과 관절염으로 인한 수종 등의 치료에 이용되며, 먹는 화장품이라고 할 만큼 피부미용에 효과가 탁월하다. The official name of Salicornia herbacea is Tungtung Madi, but it is mainly called Hamcho. It grows in tidal flats where the waters are well and relatively firm. The stem is fleshy and has a cylindrical shape. The branches are opposite to each other, and the degenerated scaly leaves are running against each other, and the nodes bulge out, resulting in the name Tungtungmadi. It is distributed all over the west coast and south coast of Korea. Green tea has long been eaten for many years, cutting the stem, boiling the soup, or grind it together with flour and knead it together to eat. Because it is rich in minerals, it is known as a health food. It removes toxins and succumbs that are accumulated in the body and has excellent therapeutic effect on cancer, uterine myoma, sinusitis, hypertension, hypotension, back pain, diabetes, bronchial asthma, hypothyroidism, hyperthyroidism, skin disease, arthritis, It is known as the amazing herb that it has. It is also used for treatment of diseases caused by inflammation and arthritis, such as eliminating sukbyeo and treating obesity, improving blood circulation, clearing blood, strengthening blood vessels, and so on. The effect is excellent.
함초에는 피토스테롤(phytosterol), 페놀산(phenolic acid), 플라보노이드(flavonoid), 다당류(polysaccharide), 디카페오일 퀴닉산(dicaffeoyl quinic acid), 프로카테츄익산(procatechuic acid), 페룰산(ferulic acid), 트리테르페노이드 사포닌(triterpenoid saponin) 등의 생리활성성분이 다양하게 함유되어 있다. 특히, 함초의 유효성분 중, 함초로부터 분리된 3-카페오일-4-다이하이드로카페오일 퀴닉산은 항산화 효과, 통풍치료, 항염증 효과, 비만, 지방간 등의 억제 효과가 있음이 있다고 보고되었다. The green tea contains phytosterol, phenolic acid, flavonoid, polysaccharide, dicaffeoyl quinic acid, procatechuic acid, ferulic acid, , Triterpenoid saponin, and the like. Particularly, among the active ingredients of green tea, 3-caffeoyl-4-dihydrocafeoylquinic acid isolated from green tea has been reported to have an antioxidant effect, gout treatment, anti-inflammatory effect, obesity and fatty liver.
HMGB1(high mobility group box 1)은 패혈증과 같은 혈관 손상이 있을 때 혈관 내피에서 발현되는 단백질로서(Toxicol. Appl. Pharm. 2012, 262, 91-98; J. Cell. Physio. 2013, 228, 975-982) 혈관내피를 염증반응 이전의 모습으로 재구성하는 역할을 하는데(Science. 1999, 285, 248-251), 본 발명자들은 함초 유래의 플라바논 또는 크로몬 유도체 화합물들이 HMGB1의 발현을 억제함으로써 혈관 염증 또는 패혈증의 치료 효과가 있음을 확인하여 본 발명을 완성하였다. HMGB1 (high mobility group box 1) is a protein expressed in the endothelium in the presence of vascular injury such as sepsis (Toxicol. Appl. Pharm. 2012, 262, 91-98; J. Cell. Physio. 2013, 228, 975 (Science, 1999, 285, 248-251), the inventors of the present invention found that flavanone or chromone derivative compounds derived from Hamcho exhibited inhibition of the expression of HMGB1, Inflammatory or sepsis, and thus the present invention has been completed.
본 발명의 목적은 함초로부터 분리된 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물을 제공하는 데에 있다. It is an object of the present invention to provide a composition for preventing or treating vascular inflammation or sepsis which contains a compound isolated from green tea.
본 발명은 하기 화학식 1의 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2), 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3), 7-히드록시-6,8-디메톡시크로몬(화합물 4), 6-메톡시크로마논(화합물 5) 및 6,7-디메톡시크로몬(화합물 6)으로 이루어진 군에서 선택되는 1종 이상의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to 7,2'- dihydroxy-6-methoxy -2 S of formula (I) - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S-flavanone ( Compound 2), 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3), 7-hydroxy-6,8-dimethoxychromone (Compound 4), 6-methoxychroma (Compound 5) and 6,7-dimethoxychromone (Compound 6). The present invention also relates to a composition for preventing or treating vascular inflammation or sepsis.
[화학식 1][Chemical Formula 1]
상기 화합물은 함초 유래의 플라바논 또는 크로몬 유도체(flavanones or chromones derivatives)로서, HMGB1(high mobility group box 1)의 발현을 억제하는 효과가 있다. These compounds are flavanones or chromone derivatives derived from Hamcho and have an effect of inhibiting the expression of HMGB1 (high mobility group box 1).
본 발명은 상기 화학식 1의 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2), 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3), 7-히드록시-6,8-디메톡시크로몬(화합물 4), 6-메톡시크로마논(화합물 5) 및 6,7-디메톡시크로몬(화합물 6)으로 이루어진 군에서 선택되는 1종 이상의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 개선용 건강기능식품을 제공한다. 상기 건강기능식품은 각종 식품류, 음료, 껌, 차 및 비타민 복합제로 이루어진 군에서 선택될 수 있다. The invention of 7,2'- dihydroxy-6-methoxy -2 S Formula 1-flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S-flavanone ( Compound 2), 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3), 7-hydroxy-6,8-dimethoxychromone (Compound 4), 6-methoxychroma (Compound 5) and 6,7-dimethoxychromone (Compound 6). The present invention also provides a health functional food for preventing or ameliorating vascular inflammation or sepsis. The health functional food may be selected from the group consisting of various foods, beverages, gums, tea and vitamin complex.
본 발명은 하기 화학식 2 내지 4의 신규 화합물 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2) 또는 7-히드록시-6,8-디메톡시크로몬(화합물 4)을 제공한다.The present invention relates to novel compounds 7,2'- dihydroxy-6-methoxy -2 S of the general formula (2) to 4-flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S -Flavanone (Compound 2) or 7-hydroxy-6,8-dimethoxychromone (Compound 4).
[화학식 2] (2)
[화학식 3](3)
[화학식 4][Chemical Formula 4]
따라서, 본 발명은 함초 추출물로부터 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2) 및 7-히드록시-6,8-디메톡시크로몬(화합물 4)으로 이루어진 군으로부터 선택되는 신규 화합물 1종 이상을 분리하는 방법을 제공할 수 있다. Accordingly, the present invention is 7,2'- dihydroxy-6-methoxy -2 S from Salicornia extract - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S-flavanone (Compound 2) and 7-hydroxy-6,8-dimethoxychromone (Compound 4).
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 상기 화학식 1의 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2), 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3), 7-히드록시-6,8-디메톡시크로몬(화합물 4), 6-메톡시크로마논(화합물 5) 및 6,7-디메톡시크로몬(화합물 6)으로 이루어진 군에서 선택되는 1종 이상의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물에 관한 것이다. The invention of 7,2'- dihydroxy-6-methoxy -2 S Formula 1-flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S-flavanone ( Compound 2), 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3), 7-hydroxy-6,8-dimethoxychromone (Compound 4), 6-methoxychroma (Compound 5) and 6,7-dimethoxychromone (Compound 6). The present invention also relates to a composition for preventing or treating vascular inflammation or sepsis.
상기 화합물은 플라바논 또는 크로몬 유도체(flavanones or chromones derivatives)로서, 함초 추출물로부터 유래된 것일 수 있다. 상기 함초 추출물은 함초를 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출 농축하여 얻은 것일 수 있다. 이 외의 추출조건은 제한되지는 않으나, 상기 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매는 함초 중량의 1~20배를 가하는 것이 바람직하며, 추출온도는 20~100℃인 것이 바람직하고, 추출시간은 1시간 내지 7일 이내가 바람직하다. 상기 함초 추출물은 상법에 따라, 물 또는 각종 유기용매에 의한 추출, 유기용매와 물의 분배, 컬럼 크로마토그래피에 의한 방법 등, 식물체 성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합한 방법을 이용하여 분획 또는 정제하여 사용할 수 있다. The compound may be flavanones or chromone derivatives, which are derived from a green tea extract. The green tea extract may be obtained by extracting green tea with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The extraction conditions are not limited, but it is preferable that the water, the lower alcohol having 1 to 4 carbon atoms, or the mixed solvent thereof is added 1 to 20 times as much as the weight of ammonia, and the extraction temperature is preferably 20 to 100 ° C , And the extraction time is preferably from 1 hour to 7 days. The above-mentioned green tea extract may be prepared by a known method which is used for extractive separation of plant components, such as extraction with water or various organic solvents, distribution of organic solvent and water, and column chromatography, May be fractionated or purified and used.
바람직하게는 상기 함초 추출물은 함초를 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출 농축하여 얻은 함초 추출물을 함초 추출물의 중량의 1~50배의 물을 가하여 현탁한 후, 상기 현탁물에 헥산, 클로로포름, 에틸아세테이트, 및, 부탄올로 이루어진 군에서 선택되는 용매를 가하여 얻은 함초 분획물로 제조할 수 있다. 상기 함초 분획물은 바람직하게는, 함초를 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출 농축하여 얻은 함초 추출물을 물에 현탁한 후 헥산과 혼합하여 얻은 헥산층의 농축물, 상기 헥산층을 제거하고 남은 잔사(물층)에 클로로포름을 혼합하여 얻은 클로로포름층의 농축물, 또는 상기 클로로포름층을 제거하고 남은 잔사(물층)에 에틸아세테이트를 혼합하여 얻은 에틸아세테이트층의 농축물, 상기 에틸아세테이트층을 제거하고 남은 잔사(물층)에 부탄올을 혼합하여 얻은 부탄올층의 농축물, 또는 상기 부탄올층을 제거하고 남은 잔사(물층)의 농축물일 수 있다. 본 발명의 화학식 1의 화합물들은 함초 추출물 또는 함초 분획물로부터 분리된 플라바논 또는 크로몬 유도체(Flavanones or Chromones derivatives) 화합물이다. 한편, 이 외의 분획조건은 제한되지는 않으나, 상기 함초 추출물에 함초 추출물의 중량의 1~50배의 물을 가하여 현탁물을 제조한 후, 상기 물과 동량의 헥산, 클로로포름, 에틸아세테이트, 및, 부탄올로 이루어진 군에서 선택되는 용매를 가하여 분획할 수 있다. 또한, 헥산층을 제거한 후 남은 잔사에 클로로포름을 가하고, 클로로포름층을 제거하고 남은 잔사에 에틸아세테이트를 가하고, 에틸아세테이트를 제거하고 남은 잔사에 부탄올을 가할 때에도, 단계적으로 이루어 질 때도 역시 잔사와 동량의 각 용매(클로로포름, 에틸아세테이트 또는 부탄올)를 순차적으로 가하여 분획할 수 있다. 이 때의 각 분획시간은 특별히 제한되지는 않으나 10분 내지 1일 이내인 것이 바람직하다. Preferably, the green tea extract is obtained by concentrating green tea extract obtained by extracting and concentrating green tea with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, adding 1 to 50 times of water to the weight of the green tea extract, suspending the green tea extract, And a green tea fraction obtained by adding a solvent selected from the group consisting of hexane, chloroform, ethyl acetate, and butanol to water. The green tea fraction is preferably a concentrate of a hexane layer obtained by suspending a green tea extract obtained by extracting and concentrating green tea with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, and then mixing with hexane, The concentrate of the chloroform layer obtained by removing the layer (chloroform) from the remaining residue (water layer) or the concentrate of the ethyl acetate layer obtained by mixing the residue (water layer) remaining after removing the chloroform layer with ethyl acetate, A concentrate of the butanol layer obtained by removing the layer and mixing butanol with the remaining residue (water layer), or a concentrate of the residue (water layer) remaining after removing the butanol layer. The compounds of formula (I) of the present invention are flavanones or chromone derivatives which are separated from green tea extract or green tea leaf fraction. In addition, other conditions for the fractionation are not limited, but it is preferable to add water to the green tea extract to 1 to 50 times the weight of the green tea extract to prepare a suspension. Then, the same amount of hexane, chloroform, ethyl acetate, Butanol can be added to the reaction mixture. Further, chloroform is added to the remaining residue after removing the hexane layer, chloroform layer is removed, and ethyl acetate is added to the remaining residue. When ethyl acetate is removed and butanol is added to the remaining residue, the same amount Each solvent (chloroform, ethyl acetate or butanol) can be added sequentially to fractionation. Each fractionation time at this time is not particularly limited, but is preferably within 10 minutes to one day.
상기 함초 추출물을 분획하거나 이로부터 본 발명의 플라바논 또는 크로몬 유도체를 분리할 때 크로마토그래피를 이용할 수 있는데, 상기 크로마토그래피는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 column chromatography), 이온교환수지 크로마토그래피(ion exchange resin chromatography), 중압 액체 크로마토그래피(MPLC; medium pressure liquid chromatography), 박층 크로마토그래피(TLC; thin layer chromatography), 실리카겔 진공 액체 크로마토그래피(silica gel vacuum liquid chromatography), 역상 크로마토그래피(reversed phase chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 중에서 선택될 수 있다. Chromatography can be used to separate the fenugreek extract or to isolate the flavanone or chromone derivative of the present invention. The chromatography can be carried out by silica gel column chromatography, Lewis-20 column chromatography (LH-20 column chromatography), ion exchange resin chromatography, medium pressure liquid chromatography (MPLC), thin layer chromatography (TLC), silica gel vacuum liquid chromatography silica gel vacuum liquid chromatography, reversed phase chromatography, and high performance liquid chromatography.
상기 함초 추출물은 함초의 전초, 뿌리, 잎, 줄기 등의 어떤 부위로부터 선택되는 모든 부위로부터 추출가능하다. The green tea extract can be extracted from any part selected from a certain part such as plantago, root, leaf, stems of green tea plant.
한편, 본 발명은 신규 화합물 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2) 또는 7-히드록시-6,8-디메톡시크로몬(화합물 4)을 제공하며, 상기 신규 화합물들을 함초로부터 분리하는 방법을 제공한다. 바람직하게는 상기 신규 화합물 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2) 또는 7-히드록시-6,8-디메톡시크로몬(화합물 4)은 함초를 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출 농축하여 얻은 함초 추출물을 물에 현탁한 후 헥산과 혼합하여 얻은 헥산층, 상기 헥산층을 제거하고 남은 잔사(물층)에 에틸아세테이트를 혼합하여 얻은 에틸아세테이트층, 상기 에틸아세테이트층을 제거하고 남은 잔사(물층)의 농축물로부터 분리될 수 있다. On the other hand, the present invention relates to novel compounds 7,2'- dihydroxy-6-methoxy -2 S - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S - flavanone ( Compound 2) or 7-hydroxy-6,8-dimethoxychromone (compound 4), and provides a method for separating the novel compounds from green tea. Preferably, the novel compounds 7,2'- dihydroxy-6-methoxy -2 S - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S - flavanone (Compound 2) or 7-hydroxy-6,8-dimethoxychromone (Compound 4) is prepared by suspending the green tea extract obtained by extracting and concentrating green tea with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, A hexane layer obtained by mixing with hexane, an ethyl acetate layer obtained by removing the hexane layer and mixing ethyl acetate in the residue (water layer) remaining, and a concentrate of the residue (water layer) remaining after removing the ethyl acetate layer .
또한, 본 발명은 상기 화학식 1의 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2), 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3), 7-히드록시-6,8-디메톡시크로몬(화합물 4), 6-메톡시크로마논(화합물 5) 및 6,7-디메톡시크로몬(화합물 6)으로 이루어진 군에서 선택되는 1종 이상의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 약학 조성물을 제공한다. The present invention is 7,2'- dihydroxy-6-methoxy -2 S of formula (I) - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S - Plastic (Compound 2), 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3), 7-hydroxy-6,8-dimethoxychromone (Compound 4) (5) and 6,7-dimethoxychromone (Compound (6)). The present invention also provides a pharmaceutical composition for preventing or treating vascular inflammation or sepsis.
상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods. Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose or lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
본 발명의 플라바논 또는 크로몬 유도체 화합물을 함유한 약학 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. 상기 화합물들은 본 발명의 약학 조성물에 바람직하게는 0.001~90 중량%, 더 바람직하게는 0.001~50 중량%, 가장 바람직하게는 0.001~30 중량%로 하여 첨가될 수 있다.The dosage of the pharmaceutical composition containing the flavanone or chromone derivative compound of the present invention will depend on the age, sex, and weight of the subject to be treated, the specific disease or condition to be treated, the severity of the disease or condition, . Dosage determinations based on these factors are within the level of ordinary skill in the art and generally the dosage ranges from 0.01 mg / kg / day to approximately 2000 mg / kg / day. A more preferable dosage is 1 mg / kg / day to 500 mg / kg / day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way. These compounds may be added to the pharmaceutical composition of the present invention in an amount of preferably 0.001 to 90% by weight, more preferably 0.001 to 50% by weight, and most preferably 0.001 to 30% by weight.
본 발명의 약학 조성물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. 본 발명의 화합물은 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있는 약제이다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection. Since the compound of the present invention has little toxicity and side effects, it can be safely used even for long-term administration for preventive purposes.
또한, 본 발명은 상기 화학식 1의 7,2'-디히드록시-6-메톡시-2S-플라바논(화합물 1), 2'-히드록시-6,7-메톡시-2S-플라바논(화합물 2), 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3), 7-히드록시-6,8-디메톡시크로몬(화합물 4), 6-메톡시크로마논(화합물 5) 및 6,7-디메톡시크로몬(화합물 6)으로 이루어진 군에서 선택되는 1종 이상의 화합물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 혈관 염증 또는 패혈증의 예방 또는 개선용 건강기능식품을 제공한다. 상기 화합물들은 본 발명의 건강기능식품에 바람직하게는 0.001~90 중량%, 더 바람직하게는 0.001~50 중량%, 가장 바람직하게는 0.001~30 중량%로 하여 첨가될 수 있다. 본 발명의 건강기능식품은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하며, 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능성식품류 등이 있다. The present invention is 7,2'- dihydroxy-6-methoxy -2 S of formula (I) - flavanone (Compound 1), 2'-hydroxy-6,7-methoxy -2 S - Plastic (Compound 2), 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3), 7-hydroxy-6,8-dimethoxychromone (Compound 4) Prevention or amelioration of vascular inflammation or sepsis, including at least one compound selected from the group consisting of ethoxychromanone (Compound 5) and 6,7-dimethoxychromone (Compound 6), and a pharmaceutically acceptable food additive additive And a health functional food. The above compounds may be added to the health functional food of the present invention in an amount of preferably 0.001 to 90% by weight, more preferably 0.001 to 50% by weight, and most preferably 0.001 to 30% by weight. The health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamins , And health functional foods.
본 발명은 함초 유래의 화합물을 함유하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물에 관한 것으로서, 상기 화합물은 플라바논 또는 크로몬 유도체(flavanones or chromones derivatives)로서, 상기 화합물은 HMGB1(high mobility group box 1)의 발현을 억제하고, CLP 수술법(cecal ligation and puncture operation)에 따른 마우스의 사망률을 억제하는 효과가 우수하여 혈관 염증 또는 패혈증의 예방 또는 치료용 의약 조성물이나 혈관 염증 또는 패혈증의 예방 또는 개선용 건강기능식품으로 용이하게 이용가능하다. The present invention relates to a composition for preventing or treating vascular inflammation or sepsis comprising a compound derived from Hamcho, wherein the compound is flavanones or chromone derivatives, wherein the compound is HMGB1 (high mobility group box 1) and inhibits the mortality of mice according to the CLP procedure (cecal ligation and puncture operation), thereby preventing or treating vascular inflammation or sepsis or preventing or improving vascular inflammation or sepsis It is easily available as a health functional food.
한편, 한국공개특허 제2005-0087418호에는 함초 유래의 3-카페오일-4-다이하이드로카페오일퀴닉산이 항염 효과가 있음이 개시된 바 있고, [강스미, 함초와 함초 종자 추출물의 항산화, 세포독성 및 항염 활성, 서울여자대학교, 2011년, 식품공학]에도 역시 함초 추출물이 갖는 항염 활성이 개시되어 있지만, 상기와 같은 항염증 효과가 있는 물질이 반드시 혈관 염증 또는 패혈증의 억제 효과가 있다고는 할 수 없다. 게다가, 본 발명에서는 함초 추출물이 아닌 함초 유래의 플라바논 또는 크로몬 유도체의 활성을 확인하는데다가, 상기 화합물들 또한 3-카페오일-4-다이하이드로카페오일퀴닉산과는 화학구조가 다른 화합물이기에, 본 발명의 화합물들이 갖는 혈관 염증 억제효과 또는 패혈증 치료 효과와 함초 추출물 또는 3-카페오일-4-다이하이드로카페오일퀴닉산이 갖는 효과는 전혀 다르다고 할 수 있다. On the other hand, Korean Patent Laid-Open No. 2005-0087418 discloses that 3-caffeoyl-4-dihydrocappa oil quinic acid derived from Hamcho has an anti-inflammatory effect. [Antioxidant, cytotoxic And anti-inflammatory activity, Seoul Women's University, 2011, Food Science and Technology] In addition, the anti-inflammatory activity of the green tea extract is also disclosed. However, the anti-inflammatory substance described above may be said to have an inhibitory effect on vascular inflammation or sepsis none. In addition, in the present invention, since the activity of flavanone or chromone derivative derived from green tea, which is not a green tea extract, is confirmed, and since these compounds are also compounds having different chemical structures from 3-caffeoyl-4-dihydrocappaheinquinic acid, The effects of the compounds of the present invention on the vascular inflammation inhibitory effect or the sepsis treatment and on the effects of the green tea extract or 3-caffeoyl-4-dihydrocafeoylquinic acid are completely different.
도 1은 본 발명의 화합물 1~6의 세포독성을 MTT 어세이를 통해 확인한 결과를 나타낸다.
도 2는 본 발명의 동물실험에 사용된 [μM/mouse]으로 표기한 화합물 1~6의 농도를 [㎍/mouse]로 환산하여 나타낸 것이다.
도 3은 패혈증 세포 모델(도 3A 및 도 3B) 또는 패혈증 동물 모델(도 3C 및 도 3D)에서 각각 본 발명의 화합물 1~6이 HMGB1의 발현을 억제하는 효과를 ELISA로 확인한 결과를 나타낸다.
도 4는 패혈증 세포 모델(도 4A) 또는 패혈증 동물 모델(도 4B)에서 각각 본 발명의 화합물 1~6이 혈관내피세포의 손상으로 인한 혈관 투과성을 억제하는 것을 확인한 결과를 나타낸다.
도 5는 패혈증 세포 모델에서 본 발명의 화합물 1~6이 세포유착분자인 VCAM-1, ICAM-1 및 E-selection의 발현(도 5A)과 세포표면 마커 수용체 TLR2(Toll-like receptor 2), TLR4(Toll-like receptor 4) 및 RAGE의 발현(도 5B)을 억제하는 것을 ELISA로 확인한 결과를 나타낸다.
도 6은 본 발명의 화합물 1~6이 혈관 염증을 억제하는 것을 나타내는 실험결과들로서, 도 6A은 본 발명의 화합물 1~6이 혈관 염증에 따른 혈관내피로의 단핵구의 이동을 억제하는 것을 확인한 결과를 나타내며, 도 6B는 본 발명의 화합물 1~6이 혈관 염증으로 인한 단핵구의 혈관내피로의 유착을 억제하는 것을 확인한 결과를 나타내고, 도 6C는 본 발명의 화합물 1~6이 HMGB1 또는 CLP로 유도된 마우스에서 혈관내피로의 백혈구 이동을 억제하는 것을 확인한 결과를 나타낸다.
도 7은 본 발명의 화합물 1~6이 TNF-α(도 7A), IL-1β(도 7B) 및 인산화된 NF-κB(phospho-NF-κB, 도 7C)의 발현을 억제하는 것을 ELISA로 확인한 결과를 나타낸다.
도 8은 본 발명의 화합물 1~6을 투여한 패혈증 동물들의 생존율을 나타낸다. Fig. 1 shows the cytotoxicity of the
2 is a graph showing the concentration of the
FIG. 3 shows the results of ELISA confirming the effect of the
FIG. 4 shows the results of confirming that the
FIG. 5 shows the expression of VCAM-1, ICAM-1 and E-selection (FIG. 5A) and the cell surface marker receptor TLR2 (Toll-like receptor 2) Inhibition of TLR4 (Toll-like receptor 4) and RAGE expression (Fig. 5B) by ELISA.
FIG. 6 shows experimental results showing that the
7 shows that compounds 1-6 of the present invention inhibit the expression of TNF-? (FIG. 7A), IL-1? (FIG. 7B) and phosphorylated NF-? B (phospho-NF-KB, FIG. 7C) It shows the result of confirmation.
Figure 8 shows the survival rate of sepsis animals treated with the compounds 1-6 of the present invention.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지고, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, the intention is to provide an exhaustive, complete, and complete disclosure of the principles of the invention to those skilled in the art.
<< 실시예Example 1. One. 함초로부터From Hamcho 화합물의 분리> Separation of compounds >
건조된 함초(Salicornia herbacea)의 지상부(aerial aerial) 8.3㎏을 메탄올 72ℓ로 실온에서 4일간 추출하고 이를 1회 더 반복한 뒤 얻은 액상들을 수집하여 여과한 후 농축하여 갈색의 슬러리 상태의 메탄올 추출물(1.9㎏)을 얻었다. 8.3 kg of aerial aerials of dried Salicornia herbacea were extracted with 72 L of methanol for 4 days at room temperature. After repeating this one more time, the resulting liquid phases were collected, filtered and concentrated to give a brown slurry of methanol extract 1.9 kg).
상기 메탄올 추출물을 모두 물(4.0ℓ)에 현탁한 후, n-헥산(3ℓ씩 가하여 4번 반복), 에틸아세테이트(3ℓ씩 가하여 4번 반복) 및 물로 순차적으로 분획하였다. 이렇게 해서 n-헥산 분획물(106.6g) 및 에틸아세테이트 분획물(45.7g)을 얻었다. All of the methanol extracts were suspended in water (4.0 L), and then sequentially fractionated with n -hexane (3 L portions were repeated 4 times), ethyl acetate (3 L portions were added 4 times) and water. Thus, n- hexane fraction (106.6 g) and ethyl acetate fraction (45.7 g) were obtained.
에틸아세테이트 분획물(45.7g)을 실리카겔 컬럼 VLC(25×18㎝)로 분리한 후 n-헥산:아세톤(100:0 → 0:100[100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 30:70, 10:90, 0:100], 10%[v/v] increment, each step 2ℓ, final washing with 6ℓ of 100% MeOH)의 농도구배 조건으로 용출하여, 10개의 소분획물[E1(1.4㎎), E2(9.3㎎), E2(1.40g), E4(1.30g), E5(1.22g), E6(1.55g), E7(2.80g), E8(5.40g), E9(9.53g), 및 E10(18.03g)]을 얻었다. The ethyl acetate fraction (45.7 g) was separated by silica gel column VLC (25 x 18 cm) and eluted with n- hexane: acetone (100: 0 to 0: 100 [100: 0, 90:10, 80:20, , 60:40, 50:50, 30:70, 10:90, 0: 100], 10% [v / v] increment, each step 2ℓ, final washing with 6ℓ of 100% MeOH) E2 (1.40 g), E4 (1.30 g), E5 (1.22 g), E6 (1.55 g), E7 (2.80 g), E8 (5.40 g), E9 (9.53 g), and E10 (18.03 g)].
소분획물 E5(2.77g)를 MPLC를 이용한 RP-C18(column Biotage SNAP Cartridge, KP-C18-HS, 400g, 75 Psi Max)로 분리한 후, 메탄올:물(60% MeOH)의 조건으로 용출하여 7개의 소분획물[E5-1(458㎎), E5-2(275㎎), E5-3(280㎎), E5-4(220㎎), E5-5(241㎎), E5-6(620㎎) 및 E5-7(600㎎)]을 얻었다. The small fraction E5 (2.77 g) was separated by RP-C18 (column Biotage SNAP Cartridge, KP-C18-HS, 400 g, 75 Psi Max) using MPLC and eluted with methanol: water (60% MeOH) Seven fractions [E5-1 (458 mg), E5-2 (275 mg), E5-3 (280 mg), E5-4 (220 mg), E5-5 (241 mg), E5-6 Mg) and E5-7 (600 mg)].
다시 소분획물 E5-3을 semi-prep HPLC로 분리하여 메탄올:물(A-B, 0-10min, 50-70% A; 10-60min, 70-80% A; 60-70min, 80-100% A)의 농도구배 조건으로 용출하여 화합물 1(t R : 26min, 7.6㎎)과 7개의 소분획물[E5-3-1(32.3㎎), E5-3-2(9.5㎎), E5-3-3(39㎎), E5-3-4(14.4㎎), E5-3-5(33.6㎎), E5-3-6(15.5㎎) 및 E5-3-7(4.2㎎)]을 얻었다. The small fraction E5-3 was further separated by semi-prep HPLC and eluted with methanol: water (AB, 0-10 min, 50-70% A; 10-60 min, 70-80% A; 60-70 min, 80-100
소분획물 E5-3-2 및 E5-3-4의 혼합물을 semi-prep HPLC로 분리하여 메탄올:물(A-B, 0-10min, 50-60% A, 10-60min, 60-68% A, 60-65min, 68-100% A) 조건으로 용출하여 화합물 2(t R : 52min, 5.2㎎)를 얻었다.The mixture of the small fractions E5-3-2 and E5-3-4 was separated by semi-prep HPLC and eluted with methanol: water (AB, 0-10 min, 50-60% A, 10-60 min, 60-68% -65min, 68-100% a) elution conditions to give the compound 2 (R t to: obtain a 52min, 5.2㎎).
소분획물 E5-4를 semi-prep HPLC하여 메탄올:물(A-B, 0-10min, 50-70% A, 10-50min, 70-80% A, 50-70min, 80-100% A) 조건으로 용출하여 8개의 소분획물[E5-4-1(17.7㎎), E5-4-2(3.2㎎), E5-4-3(3.6㎎), E5-4-4(8.0㎎), E5-4-5(10.3㎎), E5-4-6(58.4㎎), E5-4-7(9.0㎎) 및 E5-4-8(21.9㎎)]을 얻었다. The small fraction E5-4 was subjected to semi-prep HPLC and eluted with methanol: water (AB, 0-10 min, 50-70% A, 10-50 min, 70-80% A, 50-70 min, 80-100% E5-4-1 (17.7 mg), E5-4-2 (3.2 mg), E5-4-3 (3.6 mg), E5-4-4 (8.0 mg), E5-4- 5 (10.3 mg), E5-4-6 (58.4 mg), E5-4-7 (9.0 mg) and E5-4-8 (21.9 mg).
소분획물 E5-4-4를 semi-prep HPLC하여 메탄올:물(A-B, 0-10min, 50-75% A, 10-50min, 75-80% A, 50-60min, 80-100% A) 조건으로 용출하여 화합물 3(t R : 32min, 5.7㎎)을 얻었다. The small fraction E5-4-4 was subjected to semi-prep HPLC under the conditions of methanol: water (AB, 0-10 min, 50-75% A, 10-50 min, 75-80% A, 50-60 min, 80-100% eluted
소분획물 E6을 MPLC를 이용한 RP-C18(column Biotage SNAP Cartridge, KP153 C18-HS, 400g, 75 Psi Max)으로 분리하고 메탄올:물(30-50% MeOH, 6ℓ)의 농도구배 조건으로 용출하여 9개의 소분획물[E6-1(121.4㎎), E6-2(739㎎), E6-3(175㎎), E6-4(312.8㎎), E6-5(258.7㎎), E6-6(48.7㎎), E6-7(90㎎), E6-8(71.8㎎) 및 E6-9(803㎎)]을 얻었다. The small fraction E6 was separated by RP-C18 (column Biotage SNAP Cartridge, KP153 C18-HS, 400 g, 75 Psi Max) using MPLC and eluted with gradient conditions of methanol: water (30-50% MeOH, 6 L) E6-1 (121.4 mg), E6-2 (739 mg), E6-3 (175 mg), E6-4 (312.8 mg), E6-5 (258.7 mg), E6-6 ), E6-7 (90 mg), E6-8 (71.8 mg) and E6-9 (803 mg)].
소분획물 E6-2를 semi-prep HPLC로 분리하고 메탄올:물(A-B, 0-10min, 25% A; 10-15min, 25-30% A; 15-20min, 30% A; 20-25min, 30-40% A, 25-70min, 40% A; 70-85min, 40-80% A; 85-90min, 80% A; 90-100min, 80-100% A; 100-110min, 100% A)의 농도구배 조건으로 용출하여 14개의 소분획물[E6-2-1(3.1㎎), E6-2-2(0.5㎎), E6-2-3(0.4㎎), E6-2-4(40.5㎎), E6-2-5(8.7㎎), E6-2-6(16.1㎎), E6-2-7(16.1㎎), E6-2-8(31.1㎎), E6-2-9(13.3㎎), E6-2-10(16.7㎎), E6-2-11(26.1㎎), E6-2-12(11.4㎎), E6-2-13(0.6㎎) 및 E6-2-14(165.5㎎)]을 얻었다.The small fraction E6-2 was separated by semi-prep HPLC and eluted with methanol: water (AB, 0-10min, 25% A; 10-15min, 25-30% A; 15-20min, 30% 40% A, 25-70 min, 40% A, 70-85 min, 40-80% A, 85-90 min, 80% A, 90-100 min, 80-100% A, 100-110 min, 100% A) (E6-2-1 (3.1 mg), E6-2-2 (0.5 mg), E6-2-3 (0.4 mg) and E6-2-4 (40.5 mg) , E6-2-5 (8.7 mg), E6-2-6 (16.1 mg), E6-2-7 (16.1 mg), E6-2-8 (31.1 mg), E6-2-9 (13.3 mg) , E6-2-10 (16.7 mg), E6-2-11 (26.1 mg), E6-2-12 (11.4 mg), E6-2-13 (0.6 mg) and E6-2-14 (165.5 mg) ].
소분획물 E6-2-8을 semi-prep HPLC로 분리하고 메탄올:물(A-B, 0-10min: 15% A, 10-15min: 30% A, 15-60min: 30% A, 60-65min: 100% A, 65-75min: 100% A)의 농도구배 조건으로 용출하여 화합물 5(t R : 18min, 3.5㎎)를 얻었다. The small fraction, E6-2-8, was separated by semi-prep HPLC and eluted with a gradient of methanol: water (AB, 0-10 min: 15% A, 10-15 min: 30% A, 15-60 min: 30% A, 60-65 min: 100 % a, 65-75min: elution with gradient conditions of 100% a) to 5 (t R compound: was obtained 18min, 3.5㎎).
화합물 4(3.0㎎)는 소분획물 E6-2-10을 결정화한 후, 다시 메탄올 상에서 재결정화하여 순수한 형태로 얻었다. Compound 4 (3.0 mg) was crystallized in a small fraction, E6-2-10, and recrystallized on methanol to give pure product.
소분획물 E6-4 (312.8㎎)를 semi-prep HPLC로 분리하고 6㎖/min의 유속을 갖는 메탄올:물(A-B, 0-10min, 25% A; 10-15min, 25-30% A; 15-20min, 30% A; 20-25min, 30-40% A, 25-70min, 40% A; 70-85min, 40-80% A; 85-90min, 80% A; 90-100min, 80-100% A; 100-110min, 100% A)의 농도구배 조건으로 용출하여 화합물 6(t R : 65min, 3.5㎎)을 얻었다. The small fraction E6-4 (312.8 mg) was separated by semi-prep HPLC and eluted with methanol / water (AB, 0-10 min, 25% A; 10-15 min, 25-30% A; 20-40 min, 30-40% A, 25-70 min, 40% A, 70-85 min, 40-80% A, 85-90 min, 80% A, 90-100 min, 80-100 % a; 100-110min, by elution with a concentration gradient conditions of 100% a) 6 (t R compound: to obtain a 65min, 3.5㎎).
* 실시예 1의 크로마토그래피 용출액의 % 비율은 모두 [v:v]로 혼합된 혼합비율(%)을 나타냄. * The percentages of the chromatographic eluant of Example 1 all represent the mixing ratio (%) mixed in [v: v].
<실시예 2. 화합물의 물리화학적 성질 확인>≪ Example 2: Identification of physicochemical properties of a compound >
실시예 2-1. 7,2'-디히드록시-6-메톡시-2Example 2-1. 7,2'-dihydroxy-6-methoxy-2 SS -플라바논(화합물 1)- flavanone (Compound 1)
7,2'-Dihydroxy-6-methoxy-2S-flavanone; 7,2'-Dihydroxy-6-methoxy- 2 S -flavanone;
1H-NMR (600 MHz, CD3OD) 및 13C-NMR (150 MHz, CD3OD) : 표 1 참조 1 H-NMR (600 MHz, CD 3 OD) and 13 C-NMR (150 MHz, CD 3 OD): See Table 1
화합물 1(- 114.42°; c 0.05, MeOH)은 황색의 분말(yellow powder)로서 분리되었다. HR-ESI-MS 분석결과 나타난 나트륨 분자이온 피크로부터 화합물 1의 분자식은 C16H14O5로 결정된다([M+Na]+, m/z 309.1623, [calcd for C16H14O5Na]). IR 스펙트럼(KBr, νmax, ㎝-1)은 화합물 1이 히드록실 그룹(3306㎝-1), 카보닐 그룹(1656㎝-1) 및 벤젠 고리(1504, 1471, 1458㎝-1)를 갖고 있음을 나타낸다. UV-Vis 스펙트럼(MeOH, λmax(log ε))은 330 (sh), 279 (3.94) 및 237 (4.05)nm에서 최대값을 갖는 것으로 나타낸다. 화합물 1의 1H NMR 및 13C NMR 스펙트럼(표 1 참조)은 플라보노이드의 특징을 나타낸다. δ H 2.82 (dd, J = 3.3, 17.0, H-3a) 및 2.90 (dd, J = 13.0, 17.0, H-3b) (δC, 43.9, C-3)에서의 메틸렌 그룹, δH 5.73 (dd, J = 3.2, 12.9, δC, 76.7, C-2)에서의 메틴, δ C 193.8 (C-4)에서의 카보닐 그룹은 화합물 1이 플라바논임을 가리킨다. 화합물 1의 δ H 5.73 (H-2) 메틴과 δ C 155.2 (C-2')의 HMBC 상관관계 및 δ H 6.83 (H-3'), 7.17 (H-4'), 6.91 (H-5'), 7.49 (H-6')의 COSY 상관관계로부터 B-ring의 2' 위치에 히드록시 그룹을 갖는 것으로 확인된다. HMBC 분석에서 δ H 7.31 양성자와 δ C 193.8의 상관관계 신호는 5번 위치에 하이드록실 그룹의 부재를 나타내고, δ H 3.87의 메톡시 양자는 δ C 156.9의 4차 탄소에 위치하고 있음이 확인된다. 2번 위치의 절대구조는 CD 스펙트럼에서의 235.2nm의 코튼 효과(Cotton effect)에 근거하여 S 형의 절대구조인 것을 알 수 있다. 따라서, 화합물 1은 7,2'-디히드록시-6-메톡시-2S-플라바논(7,2'-dihydroxy-6-methoxy-2S-flavanone)의 구조를 갖는 신규 화합물로서 확인된다. Compound 1 ( - 114.42 DEG; c 0.05, MeOH) was isolated as a yellow powder. From the sodium molecular ion peak shown in the HR-ESI-MS analysis, the molecular formula of
실시예 2-2. 2'-히드록시-6,7-메톡시-2Example 2-2. 2'-hydroxy-6,7-methoxy-2 SS -플라바논(화합물 2)- flavanone (Compound 2)
2'-Hydroxy-6,7-methoxy-2S-flavanone;2'-Hydroxy-6,7-methoxy- 2 S -flavanone;
1H-NMR (600 MHz, CD3OD) 및 13C-NMR (150 MHz, CD3OD) : 표 1 참조 1 H-NMR (600 MHz, CD 3 OD) and 13 C-NMR (150 MHz, CD 3 OD): See Table 1
화합물 2( - 146.75°; c 0.05, MeOH)는 노란색의 분말로서 수득되었다. 화합물 2의 HR-ESI-MS 데이터에 따른 분자식은 C17H16O5([M+Na]+, m/z 323.0895 [calcd for C17H16O5Na])로 확인된다. IR 스펙트럼(KBr, νmax, ㎝-1)은 화합물 2에 히드록실 그룹(3414㎝-1), 카보닐 그룹(1651㎝-1), 벤젠 고리(1502, 1455, 1438㎝-1) 등의 특징이 있음을 보여준다. 화합물 2의 UV-Vis 스펙트럼(MeOH, λmax(log ε))은 337 (3.85), 275 (4.10) 및 237 (4.24)에서 최대값을 갖는 것으로 확인된다. 화합물 2의 1H NMR 및 13C NMR 데이터(표 1 참조)는 δ H 3.81에서의 메톡시 양자를 제외하고 화합물 1과 매우 비슷하다. 화합물 2의 HMBC 상관관계는 δ H 3.81, δ H 3.88에서의 메톡시 양자가 δ C 158.4 및 146.1의 4차 탄소와 관련이 있음을 나타낸다. 화합물 2의 C-2의 절대구조는 CD 스펙트럼에서의 299.6nm의 양성 코튼 효과(Cotton effect)에 기반하여 S형 구조인 것으로 확인된다. 따라서, 화합물 2는 2'-히드록시-6,7-메톡시-2S-플라바논(2'-hydroxy-6,7-methoxy-2S-flavanone)의 화학구조를 갖는 신규 화합물인 것으로 확인된다. Compound 2 ( - 146.75 [deg.]; c 0.05, MeOH) was obtained as a yellow powder. The molecular formula of the HR-ESI-MS data for
실시예 2-3. 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(화합물 3)Examples 2-3. 5,2'-dihydroxy-6,7-methylenedioxyflavanone (Compound 3)
5,2'-Dihydroxy-6,7-methylenedioxyflavanone;5,2'-Dihydroxy-6,7-methylenedioxyflavanone;
1H-NMR (600 MHz, CD3OD) 및 13C-NMR (150 MHz, CD3OD) : 표 2 참조 1 H-NMR (600 MHz, CD 3 OD) and 13 C-NMR (150 MHz, CD 3 OD): See Table 2
NMR 및 MS 분석결과 화합물 3은 5,2'-디히드록시-6,7-메틸렌디옥시플라바논(5,2'-dihydroxy-6,7-methylenedioxyflavanone)으로 확인된다.NMR and MS analysis showed that
실시예 2-4. 7-히드록시-6,8-디메톡시크로몬(화합물 4)Examples 2-4. 7-hydroxy-6,8-dimethoxychromone (Compound 4)
7-Hydroxy-6,8-dimethoxychromone;7-Hydroxy-6,8-dimethoxychromone;
1H-NMR (600 MHz, CDCl3) 및 13C-NMR (150 MHz, CDCl3) : 표 1 참조 1 H-NMR (600 MHz, CDCl 3 ) and 13 C-NMR (150 MHz, CDCl 3 ): See Table 1
화합물 4는 흰색의 결정형 화합물로서 수득되었다. 화합물 4의 HR-ESI-MS 데이터에 따른 분자식은 C11H10O5([M+Na]+, m/z 245.0426 [calcd for C11H10O5Na])로 확인된다. 화합물 4에 대한 1H NMR 및 13C NMR 데이터는 δ C 135.0에서의 산화된 올레피닉 4차 탄소의 존재를 제외하고, 크로몬(chromone) 화합물과 매우 비슷하다. 화합물 4의 HMBC 상관관계는 δH 7.30에서의 1개의 메틸 양자가 δ C 176.8 (C-4)에서의 카보닐 탄소와 관련이 있음을 보여주며, 이것은 H-5임이 확인된다. 이는 화합물 4의 8번 위치(position 8)가 치환되었음을 의미한다. 또한, δH 3.92 (s)와 δH 3.98 (s)에서의 두 개의 메톡시 그룹이 δ C 145.9 (C-6) 및 135.0 (C-8)의 4차 탄소와 관련이 있음을 의미한다. 따라서 화합물 4는 7-히드록시-6,8-디메톡시크로몬(7-hydroxy-6,8-dimethoxychromone)의 구조를 갖는 신규 화합물인 것으로 확인된다.
실시예 2-5. 6-메톡시크로마논(화합물 5)Examples 2-5. 6-methoxychromanone (Compound 5)
6-Methoxychromanone;6-Methoxychromanone;
1H-NMR (600 MHz, CD3OD) 및 13C-NMR (150 MHz, CD3OD) : 표 2 참조 1 H-NMR (600 MHz, CD 3 OD) and 13 C-NMR (150 MHz, CD 3 OD): See Table 2
NMR 및 MS 분석결과 화합물 5는 6-메톡시크로마논(6-methoxychromanone)으로 확인된다.NMR and MS analysis showed that
실시예Example 2-6. 6,7- 2-6. 6,7- 디메톡시크로몬Dimethoxychromone (화합물 6)(Compound 6)
6,7-Dimethoxychromone;6,7-Dimethoxychromone;
1H-NMR (600 MHz, CD3OD) 및 13C-NMR (150 MHz, CD3OD) : 표 2 참조 1 H-NMR (600 MHz, CD 3 OD) and 13 C-NMR (150 MHz, CD 3 OD): See Table 2
NMR 및 MS 분석결과 화합물 6은 6,7-디메톡시크로몬(6,7-dimethoxychromanone)으로 확인된다.NMR and MS analysis confirmed that
(dd, J = 12.9, 3.2) 5.73
(dd, J = 12.9, 3.2)
(d, J = 2.5)5.74
(d, J = 2.5)
(d, J = 5.9)7.79
(d, J = 5.9)
(dd, J = 17.0, 3.3)
2.90
(dd, J = 17.0, 13.0)2.82
(dd, J = 17.0,3.3)
2.90
(dd, J = 17.0, 13.0)
(d, J = 2.3)2.80
(d, J = 2.3)
(d, J = 5.9)6.23
(d, J = 5.9)
(d, J = 8.1)6.83
(d, J = 8.1)
(dd, J = 8.1, 0.7)6.83
(dd, J = 8.1, 0.7)
(dt, J = 7.8, 1.5)7.17
(dt, J = 7.8, 1.5)
(td, J = 7. 9, 1.6)7.17
(td, J = 7.9, 1.6)
(dt, J = 7.6, 0.7)6.89
(dt, J = 7.6, 0.7)
(d, J = 7.7)7.49
(d, J = 7.7)
(dd, J = 7.7, 1.4)7.51
(dd, J = 7.7,1.4)
- The coupling constant J values (in hertz) are given in parentheses.
- All assignments are based on the COSY, HMQC, and HMBC experiment.- The chemical shifts (δ) are in ppm from TSM.
- The coupling constant J values (in hertz) are given in parentheses.
- All assignments are based on the COZY, HMQC, and HMBC experiment.
2.98 dd (13.3, 17.2)2.79 dd (3.0, 17.2)
2.98 dd (13.3, 17.2)
<< 실시예Example 3. 세포독성 확인> 3. Cytotoxicity>
본 발명의 화합물들이 세포독성이 있는지를 확인하기 위해, MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 어세이를 수행하였다. HUVEC(Human umbilical vein endothelial cells)을 96웰 플레이트에 웰당 5×103개로 분주한 후, 24시간 후에, ESM(effective screening medium) 배양액으로 교체하였다(HUVEC 세포는 Cambrex Bio Science(Charles City, IA, USA)에서 얻었으며, EBM-2 기본 배지(basal media) 및 이에 공급되는 성장 보충물(Cambrex Bio Science)을 첨가하여 배양 유지한다). 이 때 본 발명의 화합물 1~6을 최종농도가 1~20μM이 되도록 처리하고, 48시간 후, 100㎕의 1㎎/㎖ MTT 용액을 세포에 더하여 4시간 동안 반응시켰다. 이 후 DMSO(dimethyl sulfoxide) 150㎕를 더하여, 세포 내에 생성된 포마잔염(formazan salt)을 용해시킨 후, 이 포마잔의 양을 Microplate reader(Tecan Austria GmbH, Austria)를 이용하여 540nm에서 측정하였고, 이에 대한 결과는 도 1에 나타내었다. (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) assay was performed to confirm that the compounds of the present invention were cytotoxic. HUVEC (Human umbilical vein endothelial cells), and then a frequency divider in a 96-well plate per well 5 × 10 3 dogs, 24 hours later, ESM (effective screening medium) was replaced with culture medium (HUVEC cells Cambrex Bio Science (Charles City, IA, USA) and incubated with EBM-2 basal media and growth supplement (Cambrex Bio Science) supplied thereto. At this time, the
도 1을 참고하면, 본 발명의 화합물 1~6은 모두 세포독성이 없는 것으로 확인된다. Referring to FIG. 1, it is confirmed that all of the
<< 실시예Example 4. 패혈증 동물모델 유도> 4. Induction of sepsis animal models>
마우스의 맹장을 터트리는 CLP 수술법(cecal ligation and puncture operation)을 이용하여 마우스에 패혈증을 유도하였다. CLP 수술에 이용된 마우스는 수컷 C57BL/6 마우스를 이용하였고, 각 군당 10마리씩 이용하였다(6~7주령 및 체중 18~20g의 마우스를 구입하고 12일간 실험실에서 순응화한 후 사용, Orient Bio Co. Sungnam, Kyungki-Do, Republic of Korea). 마우스를 졸레틸 50(zoletil 50) 및 3%(w/v) 이소플루란(isoflurane, Forane®, Choongwae Pharma. Corp., Seoul, Korea)으로 마취시켰다. 패혈증 모델을 유도하기 위해 배 부위 2㎝를 절개하여 맹장과 근처의 창자를 노출시켰다. 맹장 끝으로부터 5㎜ 부위의 맹장을 3.0-실크 봉합선으로 강하게 묶고, 22-게이지 바늘로 이를 터트렸다. 맹장을 부드럽게 짜 내어 천공 부위를 통해 소량의 배설물(장내 소화물)이 누출되게 하였고, 이 배설물을 복강에 노출시켰으며, 개복부위를 4.0-실크 봉합선으로 봉합하였다. 대조군(sham, sham-operated mice)은 맹장을 묶고 터트리는 단계를 수행하지 않고 단순히 배만 절개하고 다시 봉합하였다. 각 마우스들은 CLP 수술 24시간 후부터 패혈증 증상에 노출되었는데, 전율(shivering)이 있거나 털이 곤두서거나(bristled hair) 또는 무기력증(weakness) 등의 현상이 나타났다. Sepsis was induced in mice using a cecal ligation and puncture operation that exploded the mouse's cecum. The mice used for CLP surgery were male C57BL / 6 mice, and 10 mice were used per group (6 ~ 7 weeks old and 18 ~ 20g mice were purchased and adapted for 12 days in a laboratory. After using Orient Bio Co Sungnam, Kyungki-Do, Republic of Korea). Mice were anesthetized with
<< 실시예Example 5. 패혈증 모델에서의 5. In the sepsis model HMGB1HMGB1 발현 확인> Expression confirmation>
실시예Example 5-1. 패혈증 세포모델의 5-1. Sepsis cell model HMGB1HMGB1 발현 확인 Confirmation of expression
HUVEC을 6웰 플레이트(6-well plates)에서 배양한 후 LPS(lipopolysaccharide, 100ng/㎖)를 4시간 동안 처리하였으며(대조군은 saline 처리), 이 후, 본 발명의 화합물 1 내지 6을 1~10μM로 6시간 동안 처리하였다. HUVECs were cultured in 6-well plates and treated with LPS (lipopolysaccharide, 100 ng / ml) for 4 hours (control group treated with saline) For 6 hours.
HUVEC의 세포배양액을 이용하여 ELISA(competitive enzyme-linked immunosorbent assays)를 수행하기 위해 96웰 플레이트(96-well plastic flat microtiter plates, Corning, NY, USA)에 0.02% 소듐 아자이드(sodium azide)가 포함된 20mM 카보네이트/바이카보네이트완충용액(carbonate/bicarbonate buffer, pH 9.6)에 녹인 HMGB1 단백질(Abnova)을 코팅하여 4℃에서 18시간 이상 밤을 지새워 반응하였다. 이 후, 플레이트를 PBS-T(PBS-0.05%[w/w] Tween 20)로 3번 세척한 후, PBS-T를 넣어서 4℃에서 18시간 이상 밤을 지새워 보관하였다. In a 96-well plastic flat microtiter plates (Corning, NY, USA), 0.02% sodium azide was added to perform competitive enzyme-linked immunosorbent assays (HUVEC) HMGB1 protein (Abnova) dissolved in 20 mM carbonate / bicarbonate buffer (pH 9.6) was coated and reacted overnight at 4 ° C for 18 hours or more. After that, the plate was washed 3 times with PBS-T (PBS-0.05% [w / w] Tween 20), then PBS-T was added and kept overnight at 4 ° C for 18 hours or more.
한편, HMGB1 단백질(Abnova, 단백질 정량용, PBS-T에 희석), HUVEC의 세포배양액(conditioned culture media)(LPS 처리된 샘플 포함)은 각각 96웰 플레이트에서 항-HMGB1 항체(Abnova, PBS-T에 1:1000 희석)와 37℃에서 90분간 전반응시켰다. 상기 HUVEC의 세포용출액은 1mM PMSF, 1mM Na3VO4, 1mM NaF, 1㎍/㎖ 아프로티닌(aprotinin), 1㎍/㎖ 펩스타틴(pepstatin), 1㎍/㎖ 류펩틴(leupeptin) 및 10% RIPA 용해 버퍼(Upstate Biotechnology, USA)를 함유하고 있는 단백질 분리 시약을 이용해 4℃에서 1시간 동안 볼텍싱(vortexing)하여 분해시킨 후 원심분리(15000 rpm, 4℃, 20분)하여 얻은 상층액이다.HMGB1 protein (for Abnova, dilution in PBS-T for protein determination) and HUVEC conditioned culture media (including LPS-treated sample) were incubated with anti-HMGB1 antibody (Abnova, PBS-T At 1: 1000 dilution) at 37 < 0 > C for 90 minutes. The HUVEC cell extracts contained 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF, 1 μg / ml aprotinin, 1 μg / ml pepstatin, 1 μg / ml leupeptin and 10% The supernatant was obtained by centrifugation (15000 rpm, 4 ° C, 20 minutes) after decomposition by vortexing at 4 ° C for 1 hour using a protein separation reagent containing RIPA dissolution buffer (Upstate Biotechnology, USA) .
상기 항체가 전반응된 HMGB1 단백질, HUVEC의 세포배양액을 HMGB1이 코팅된 플레이트로 옮겨 실온에서 30분간 반응시켰다. 이 후, 각 플레이트들은 PBS-T로 3번 세척하였고, 실온에서 90분간 2차 항체(peroxidase-conjugated anti-rabbit IgG antibodies, R&D Systems, PBS-T에 1:2000 희석)와 반응시켰다. The cell culture of HMGB1 protein, HUVEC, which had been reacted with the antibody, was transferred to a plate coated with HMGB1, and reacted at room temperature for 30 minutes. Each plate was then washed three times with PBS-T and reacted with secondary antibodies (peroxidase-conjugated anti-rabbit IgG antibodies, 1: 2000 dilution in R & D Systems, PBS-T) for 90 minutes at room temperature.
각 플레이트들을 PBS-T로 3번 세척한 후, 실온의 암실에서 60분간 200㎕씩의 기질용액(100㎍/㎖ o-phenylenediamine & 0.003% H2O2)을 처리하였다. 다음으로는 8N의 H2SO4 50㎕를 가하여 모든 반응을 중단시킨 후, 490nm에서 흡광도를 확인하였으며, 분석결과는 도 3A 및 도 3B에 나타내었다. Each plate was washed three times with PBS-T and treated with 200 μl of substrate solution (100 μg / ml o- phenylenediamine & 0.003% H 2 O 2 ) for 60 minutes in a dark room at room temperature. Next, 50 μl of 8N H 2 SO 4 was added to stop all the reactions, and the absorbance was confirmed at 490 nm. The analysis results are shown in FIGS. 3A and 3B.
도 3A 및 도 3B를 참고하면, 패혈증 세포 모델에서 본 발명의 화합물들이 LPS가 처리된 HUVEC에서 본 발명의 화합물 1~6이 HMGB1의 발현을 현저하게 억제하는 효과가 있는 것으로 확인된다. 3A and 3B, it is confirmed that the compounds of the present invention in the sepsis cell model have the effect of inhibiting the expression of HMGB1 remarkably in the HUVEC treated with LPS.
실시예Example 5-2. 패혈증 동물모델의 혈중 5-2. Sepsis HMGB1HMGB1 발현 확인 Confirmation of expression
실시예 4의 방법으로 CLP 수술을 수행한 마우스에 본 발명의 화합물 1 내지 6(1~10μM/mouse)을 정맥투여하였다(CLP 수술을 수행 후 12시간 후에 투여). Mice treated with CLP according to the method of Example 4 were intravenously administered with
* 동물실험에 사용된 각 화합물의 [μM/mouse] 값과 [㎍/mouse] 값의 환산값은 도 2에 개시되어 있음.The values of [μM / mouse] and [μg / mouse] of each compound used in the animal experiment are shown in FIG.
CLP 수행 24시간 후 마우스를 희생하여 혈액을 채취한 후 2000×g에서 5분간 원심분리하여 혈청 샘플을 얻었다. ELISA 과정은 실시예 5-1과 동일하게 수행하였고, 분석 결과는 도 3C 및 도 3D에 나타내었다. After 24 hours of CLP, the mice were sacrificed and blood was collected and centrifuged at 2000 xg for 5 minutes to obtain serum samples. The ELISA procedure was performed in the same manner as in Example 5-1, and the analysis results are shown in FIGS. 3C and 3D.
도 3C 및 도 3D를 참고하면, CLP 수술법으로 유도된 패혈증 동물에서 본 발명의 화합물 1~6이 HMGB1의 발현을 현저하게 억제하는 효과가 있는 것으로 확인된다. 3C and 3D, it was confirmed that the
<< 실시예Example 6. 6. 혈관세포의Vascular cell 투과성 억제 효과 확인> Confirmation of permeation inhibiting effect>
실시예Example 6-1. 패혈증 세포모델에서의 6-1. In the sepsis cell model 혈관세포의Vascular cell 투과성 억제 효과 확인 Confirm permeation inhibiting effect
본 발명의 화합물 1~6(10μM)을 HUVEC에 처리한 후 각 화합물이 HMGB1을 통해 유도된 혈관벽 손상(혈관의 미세한 천공으로 인해 투과성이 생김)을 복구하는지를 확인하였다. 이를 위해 2-챔버 모델(2-compartment chamber model, Blood 2011, 118, 3952-3959)을 이용해 배양된 세포층에서의 에반스 블루와 결합된 알부민(Evans blue-bound albumin)의 흐름을 정량적으로 측정하였다.
HUVEC은 5×104/웰(well)로 3㎛의 기공(pore) 크기를 갖는 12㎜ 직경의 트랜스웰(transwell)에서 3일 동안 배양되었다. 세포가 각 트랜스웰에 가득 차면 LPS(100ng/㎖, 4시간) 또는 HMGB1(1㎍/㎖, 16시간)을 처리하여 반응시켰고, 각각의 화합물을 6시간 동안 처리하였다. 이 후 각 트렌스웰을 PBS(pH 7.4)로 세척하였고, 4%(w/v) BSA가 포함된 세포배양배지에 희석된 0.5㎖의 에반스 블루 용액(0.67㎎/㎖)을 준비하였다. 신선한 세포배양배지가 하단의 챔버에 더해졌고, 상단의 챔버에는 상기 에반스 블루 용액으로 교체되었다. 10분 후, 하단 챔버의 OD(Optical density)를 650nm에서 측정하였고 이에 대한 결과는 도 4A에 나타내었다. HUVECs were cultured for 3 days in a 12 mm diameter transwell with a pore size of 3 [mu] m at 5 x 10 < 4 > / well. When cells were filled in each transwell, LPS (100 ng / ml, 4 hours) or HMGB1 (1 μg / ml, 16 hours) was treated and reacted, and each compound was treated for 6 hours. Each transwell well was then washed with PBS (pH 7.4) and 0.5 ml of Evans blue solution (0.67 mg / ml) diluted in cell culture medium containing 4% (w / v) BSA was prepared. Fresh cell culture medium was added to the lower chamber, and the upper chamber was replaced with the above Evans blue solution. After 10 minutes, the OD (optical density) of the lower chamber was measured at 650 nm and the results are shown in FIG. 4A.
도 4A를 확인하면, 본 발명의 화합물 1~6이 모두 세포 손상으로 인한 투과성(에반스 블루 용액의 흐름)을 억제하는 것을 확인할 수 있어, HMGB1로 유도된 패혈증 세포 모델에서의 혈관 염증 억제 효과가 우수함을 알 수 있다. 4A, it can be confirmed that the
실시예Example 6-2. 패혈증 동물모델에서의 6-2. In an animal model of sepsis 혈관세포의Vascular cell 투과성 억제 효과 확인 Confirm permeation inhibiting effect
수컷 C57BL/6 마우스를 준비하고(각 군당 10마리씩 준비, 6-7주령 및 체중 18~20g의 마우스를 구입하고 12일간 실험실에서 순응화한 후 사용, Orient Bio Co. Sungnam, Kyungki-Do, Republic of Korea), 상기 마우스에 각 시료(10μM/mouse)를 정맥주사를 통해 처리하고 6시간 후 살린(saline) 용액에 녹인 1%(w/v) 에반스 블루 용액과 HMGB1(2㎍/mouse)를 연이어 정맥주사하였다. Male C57BL / 6 mice were prepared (10 mice per group, 6-7 weeks old and 18-20g mice were purchased and adapted for 12 days in a laboratory, using Orient Bio Co., Sungnam, Kyungki-Do, Republic (2 μg / mouse) of Evans Blue solution and 1% (w / v) Evans Blue solution dissolved in saline solution at 6 hours after intravenous injection of each sample (10 μM / mouse) Followed by intravenous injection.
에반스 블루 용액을 정맥주사한 지 2시간 후 마우스를 희생시키고, 복강을 5㎖의 살린 용액으로 세척하면서 복막 삼출물(peritoneal exudate)을 모아 200×g에서 10분간 원심분리하였다. 상기 원심분리물의 상층액(supernatant)의 흡광도는 650nm에서 확인하였다. 이는 에반스 블루 용액의 염료가 복강 내로 흘러나온 것을 통해 혈관세포에 생긴 미세천공으로 인한 투과성을 확인할 수 있기 때문이다(Int. Immunopharmacol. 2009, 9, 268-276.). 상기 결과는 도 4B에 나타내었다. Two hours after the intravenous injection of Evans Blue solution, the mice were sacrificed and the peritoneal exudate was collected by centrifugation at 200 xg for 10 minutes while the abdominal cavity was washed with 5 ml of saline solution. The absorbance of the supernatant of the centrifuge was confirmed at 650 nm. This is because the dye of the Evans blue solution flows into the abdominal cavity and can confirm the permeability due to the microperforations in the vascular cells (Int. Immunopharmacol. 2009, 9, 268-276.). The results are shown in FIG. 4B.
상기 도 4B를 참고하면, HMGB1이 처리된 마우스에서는 다량의 염색약 누출이 있는 것을 알 수 있는데, 상기 마우스에 화합물 1 내지 6이 처리된 군에서는 염색약의 누출이 현저하게 억제되었음을 알 수 있다. 이에 상기 화합물들이 혈관벽 손상을 보호함으로써 패혈증을 억제함을 입증할 수 있다. Referring to FIG. 4B, it can be seen that there is a large amount of dye leakage in the HMGB1-treated mouse. In the group treated with the
<< 실시예Example 7. 7. 세포유착분자Cell adhesion molecule 및 세포표면 And cell surface 마커Marker 수용체의 발현 확인> Confirmation of receptor expression>
VCAM-1(vascular cell adhesion molecule-1), ICAM-1(intercellular adhesion molecule-1), E-selection과 같은 세포유착과 관련된 단백질의 발현을 whole-cell ELISA 방법으로 확인하였다. The expression of proteins related to cell adhesion such as VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1) and E-selection was confirmed by whole-cell ELISA.
세포가 90%의 confluence를 이루면 96웰 플레이트에 배양한 HUVEC에 HMGB1(1㎍/㎖)을 16시간 동안 반응시키고, 본 발명의 화합물 1~6(10μM)을 6시간 동안 처리하였다. 이 후, 세포배양액을 제거하고, 세포를 PBS(phosphate buffered saline)로 세척한 후, 각 세포를 50㎕의 1%(w/v) 파라포름알데히드(paraformaldehyde)로 15분간 25℃ 실온에서 고정하였다. 1%(w/v) 파라포름알데히드를 제거하고 세포를 세척한 후, VCAM-1, ICAM-1 또는 E-selection에 대한 마우스 항 인간 모노클로널 항체(mouse anti human monoclonal antibody, Temecula, CA, USA, 1:50 희석) 100㎕를 가하였다. 1시간 후에는 각 세포를 3번씩 세척하고, 100㎕의 1:2000 퍼옥시다아제-결합 항-마우스 IgG 항체(1:2000 peroxidase-conjugated anti-mouse IgG antibody, Sigma, Saint Louis, MO)와 1시간 동안 반응시켰고, 3번 세척한 후, o-PPD 기질(o-phenylenediamene substrate, Sigma, St. Louis, MO)과 반응시켰다. 이로 인해 나타나는 발색반응에 대한 흡광도를 490nm에서 측정하였고, 도 5A에 나타내었다. 또한, 혈관내피세포에서 혈관 염증이 일어날 때 발현하는 세포표면(cell surface) 마커인 TLR2(Toll-like receptor 2), TLR4(Toll-like receptor 4) 및 RAGE(Receptor for advanced glycation end products) 수용체의 발현도 각 마커에 대해 A-9, H-80 및 A-9 항체(Santa Cruz, CA)를 이용하여 이와 동일한 방법으로 확인하였으며, 이에 대한 결과는 도 5B에 나타내었다. When cells were confluent at 90%, HMGB1 (1 / / ml) was incubated in HUVEC cultured on a 96-well plate for 16 hours, and the
도 5A 및 도 5B를 참고하면, 본 발명의 화합물 1~6이 패혈증 세포 모델에서 세포유착분자인 VCAM-1, ICAM-1 및 E-selection(도 5A)과 세포표면 마커 수용체 TLR2(Toll-like receptor 2), TLR4(Toll-like receptor 4) 및 RAGE(도 5B)의 발현을 현저하게 억제하는 것으로 확인되어, 상기 화합물들의 혈관 염증 억제효과가 아주 우수함을 알 수 있다. 5A and 5B, Compounds 1 to 6 of the present invention inhibited cell adhesion molecules VCAM-1, ICAM-1 and E-selection (FIG. 5A) and cell surface marker receptor TLR2 (Toll-like receptor 2), TLR4 (Toll-like receptor 4) and RAGE (FIG. 5B), and thus the compounds are shown to exhibit excellent vascular inflammation inhibitory effects.
<< 실시예Example 8. 혈관 염증에 따른 혈관내피로의 단핵구 및 백혈구의 이동 확인> 8. Identification of monocyte and leukocyte migration into vascular endothelium following vascular inflammation>
실시예Example 8-1. 혈관 염증에 따른 혈관내피로의 단핵구의 이동 확인 8-1. Identification of monocyte migration into vascular endothelium following vascular inflammation
혈관 염증에 따른 혈관내피로의 단핵구(monocyte)의 이동 현상을 확인하기 위해, 8㎛의 기공(pore) 크기를 갖는 필터가 내장된 직경 6.5㎜의 트랜스웰 플레이트(transwell plate)를 이용하였다. 상기 트렌스웰 플레이트의 필터 아래의 하단 챔버에 HUVEC(6×104/cells)을 3일간 배양하여, 세포배양 플레이트에 세포가 가득차게 하였다. 단핵구인 THP-1 세포도 역시 HUVEC이 배양되는 플레이트 층의 상단 챔버에서 배양하였는데, 이 THP-1 세포를 상단 챔버에 넣기 전에 HUVEC에 HMGB1(1㎍/㎖)을 처리하였다(THP-1 세포는 2×105~1×106세포/㎖의 밀도로 L-글루타민이 포함된 RPMI1640 배지(FBS 10%[v/v], 2-머캅토에탄올 55μM 포함)에서 배양 유지됨). HMGB1을 HUVEC와 16시간 동안 반응시키고, 본 발명의 화합물 1~6(10μM)을 6시간 동안 처리하였다. 이후, 필터 아래로 이동하지 않은 위쪽 챔버에 있던 세포들을 제거하고, 하단 챔버 쪽의 필터 위로 이동한 단핵구 세포들을 8%(w/v) 글루타르알데히드(glutaraldehyde)로 고정한 후, 20%(v/v) 메탄올 수용액에 녹인 0.25%(w/v) 크리스탈 바이올렛(crystal violet) 용액으로 염색하였다. 염색결과는 광학현미경을 이용하여 육안으로 확인하였고, 이동지수(migration index)를 참고하여 단핵구의 이동정도를 도 6A에 나타내었다. To confirm the migration of monocytes to vascular endothelium following vascular inflammation, a 6.5 mm diameter transwell plate with a filter having a pore size of 8 mu m was used. HUVEC (6 x 10 < 4 > / cells) was cultured in the lower chamber below the filter of the transfer well plate for 3 days, and the cell culture plate was filled with cells. Monocyte THP-1 cells were also cultured in the upper chamber of the plate layer where the HUVECs were cultured. HUVECs were treated with HMGB1 (1 μg / ml) before the THP-1 cells were placed in the upper chamber (THP- Maintained in RPMI 1640 medium (containing 10% FBS [v / v], 55 μM 2-mercaptoethanol) containing L-glutamine at a density of 2 × 10 5 to 1 × 10 6 cells / HMGB1 was reacted with HUVEC for 16 hours, and compounds 1 to 6 (10 μM) of the present invention were treated for 6 hours. Then, the cells in the upper chamber that did not move under the filter were removed, and the mononuclear cells migrated on the filter in the lower chamber side were fixed with 8% (w / v) glutaraldehyde, v) 0.25% (w / v) crystal violet solution dissolved in an aqueous methanol solution. The results of the staining were visually confirmed using an optical microscope and the degree of migration of mononuclear cells with reference to the migration index was shown in FIG. 6A.
도 6A를 참고하면, 본 발명의 화합물 1~6이 혈관 염증에 따른 혈관내피로의 단핵구의 이동을 현저하게 억제하는 것으로 확인된다. Referring to FIG. 6A, it was confirmed that the
실시예Example 8-2. 혈관 염증으로 인한 단핵구의 혈관내피로의 유착 확인 8-2. Confirmation of monocyte adhesion to vascular endothelium due to vascular inflammation
혈관내피세포에 대한 단핵구의 유착 확인을 위해, THP-1 세포(1.5×106/㎖, 200㎕/well)를 Vybrant DiD 염료로 표지한 후, HUVEC 세포에 더하여 배양하였다. To confirm adhesion of mononuclear cells to vascular endothelial cells, THP-1 cells (1.5 × 10 6 / ml, 200 μl / well) were labeled with Vybrant DiD dye and then added to HUVEC cells.
이를 위해, 먼저 HUVEC에 HMGB1(1㎍/㎖)을 16시간 동안 반응시키고, 본 발명의 화합물 1~6(10μM)을 6시간 동안 처리하였다. 이 후, Vybrant DiD 염료로 표지된 THP-1 세포를 더하여 37℃에서 1시간 동안 배양하였으며, 유착되지 않은 세포들은 세포배지를 이용하여 세척하였고, HUVEC과 THP-1 세포의 유착 정도를 형광현미경으로 확인하였고, 이에 대한 결과는 도 6B에 나타내었다. For this, HUVEC was first reacted with HMGB1 (1 / / ml) for 16 hours, and the
도 6B를 참고하면, 본 발명의 화합물 1~6이 혈관 염증으로 인한 단핵구의 혈관내피로의 유착을 현저하게 억제하는 것으로 확인된다. Referring to FIG. 6B, it was confirmed that
실시예Example 8-3. 혈관내피로의 백혈구 이동 확인 8-3. Identification of leukocyte migration into vascular endothelium
백혈구의 이동을 측정하기 위해서는 마우스에 본 발명의 화합물 1~6(10μM/mouse)을 정맥주사한 후, HMGB1(2㎍/mouse)을 6시간 후에 정맥주사하였다. In order to measure the migration of leukocytes,
또한, 실시예 4의 방법으로 CLP 수술을 수행한 마우스에 본 발명의 화합물 1 내지 6(10μM/mouse)을 정맥투여하였다(CLP 수술을 수행 후 12시간 후에 투여). In addition, the
이 후, 각 마우스를 희생하여 복막강을 살린 용액으로 세척하여 복막 삼출액을 수집한 후, 복막 삼출액 20㎕를 0.38㎖의 Turk’ solution (0.01 % crystal violet in 3 % acetic acid)과 혼합하여 형광 현미경을 통해 확인되는 백혈구의 수를 육안으로 관찰하였다. 이에 대한 결과는 도 6C에 나타내었다. After the peritoneal effusion was collected, 20 μl of the peritoneal effusion was mixed with 0.38 ml of Turk 'solution (0.01% crystal violet in 3% acetic acid) And the number of white blood cells identified through the eye was visually observed. The results are shown in Fig. 6C.
도 6C를 참고하면, 본 발명의 화합물 1~6이 HMGB1 또는 CLP로 유도된 마우스에서 혈관내피로의 백혈구 이동이 억제되어 혈관내피에서의 백혈구 수가 현저하게 줄어들었음을 확인할 수 있다. Referring to FIG. 6C, it can be confirmed that the
<< 실시예Example 9. 염증 관련 인자의 발현 확인> 9. Expression of inflammatory factors>
HUVEC에 본 발명의 화합물 1~6(10μM)을 6시간 동안 처리하였고, 이 후 다시 HMGB1(1㎍/㎖, 16시간)을 처리하여 반응시켰다. 각 염증인자의 발현은 ELISA 키트를 이용하여 확인하였고, 이에 대한 결과는 도 7에 나타내었다.
* TNF-α 및 IL-1β(R&D Systems, Minneapolis, MN, USA), Total-NF-κB 및 phospho-NF-κB(#7174, #7173, Cell Signaling Technology, Danvers, MA, USA).TNF-? And IL-1? (R & D Systems, Minneapolis, MN, USA), Total-NF-κB and phospho-NF-κB (# 7174, # 7173, Cell Signaling Technology, Danvers, MA, USA).
도 7을 참고하면, 본 발명의 화합물 1~6이 TNF-α, IL-1β 및 인산화된 NF-κB(phospho-NF-κB)의 발현을 억제하여 혈관 염증의 치료효과가 우수함을 확인할 수 있다. 7, the
<< 실시예Example 10. 패혈증 동물모델에서의 생존율 확인> 10. Determine survival rate in sepsis animal models>
실시예 4의 방법으로 CLP 수술을 수행한 마우스에 본 발명의 화합물 1~6(10μM/mouse)을 2회 정맥투여하였다(CLP 수술을 수행 후 12시간 및 50시간, 총 2회 투여)(각 군당 20마리). 마우스의 생존은 CLP 수술을 수행한 지 6시간 후부터 126시간까지 확인하였고(카플란-마이어의 생존 분석법[Kaplan-Meier survival analysis]에 따라 관찰), 시간에 따른 마우스의 생존결과는 도 8에 나타내었다.
도 8을 참고하면, 본 발명의 화합물 1~6을 투여한 마우스 그룹은 모든 화합물에서 CLP 수술 이후 126시간째에 각각 40~60%의 생존율을 갖는 것으로 확인되어 패혈증의 치료 효과가 우수함을 알 수 있다.Referring to FIG. 8, it was found that the mouse group administered with the
<실시예 11. 독성실험> ≪ Example 11: Toxicity test &
실시예 11-1. 급성독성Example 11-1. Acute toxicity
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 단기간에 과량을 섭취하였을 때 급성적(24시간 이내)으로 동물체내에 미치는 독성을 조사하고, 치사율을 결정하기 위하여 본 실험을 수행하였다. 일반적인 마우스인 ICR 마우스 계통을 각 군당 10마리씩 배정하였다. 대조군에는 PEG-400:Tween-80:에탄올(8:1:1, v:v:v) 만을 투여하고, 실험군은 본 발명의 화합물 1 또는 화합물 4를 상기 PEG-400:Tween-80:에탄올(8:1:1, v:v:v)에 녹여 각각 경구투여하였다. 투여 24시간 후에 각각의 치사율을 조사한 결과, 대조군과 2g/㎏/day 농도의 본 발명의 화합물 1 또는 화합물 4를 투여한 실험군에서 마우스가 모두 생존하는 것으로 확인되었다.(7,2'-dihydroxy-6-methoxy-2 S -flavanone) or compound 4 (7-hydroxy-6,8-dimethoxychromone) of the present invention in a short period of time (Within 24 hours) to determine toxicity to the animal body, and to determine the mortality rate. An ICR mouse line, a common mouse, was assigned to each group of 10 mice. In the control group, only the PEG-400: Tween-80: ethanol (8: 1: 1, v: v: 8: 1: 1, v: v: v). After 24 hours of administration, the respective mortality rates were examined. As a result, it was confirmed that mice were all alive in the control group and the test group to which
실시예 11-2. 실험군 및 대조군의 장기 및 조직 독성 실험Example 11-2. Organ organs toxicity test in experimental group and control group
장기 독성 실험은 본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 각 농도로 8주 동안 C57BL/6J 마우스(각 군당 10마리)에 투여하여 실험하였다. 동물의 각 장기(조직)에 미치는 영향을 조사하기 위하여 본 발명의 화합물 1 또는 화합물 4를 투여한 실험군과 PEG-400:Tween-80:에탄올(8:1:1, v:v:v)만을 투여한 대조군의 동물들로부터 8주 후 혈액을 채취하여 GPT(glutamate-pyruvate transferase) 및 BUN(blood urea nitrogen)의 혈액 내 농도를 Select E(Vital Scientific NV, Netherland) 기기를 이용하여 측정하였다. 그 결과, 간독성과 관계있는 것으로 알려진 GPT와 신장독성과 관계있는 것으로 알려진 BUN의 경우, 대조군과 비교하여 실험군은 별다른 차이를 보이지 않았다. 또한, 각 동물로부터 간과 신장을 절취하여 통상적인 조직절편 제작과정을 거쳐 광학현미경으로 조직학적 관찰을 시행하였으며 모든 조직에서 특이한 이상이 관찰되지 않았다. The long-term toxicity test was carried out using the compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or the compound 4 (7-hydroxy-6,8-dimethoxychromone) C57BL / 6J mice (10 mice per group) for 8 weeks. (8: 1: 1, v: v: v) alone or in combination with a test group to which
<제제예 1. 약학적 제제>≪ Formulation Example 1 >
제제예 1-1. 정제의 제조Formulation Example 1-1. Manufacture of tablets
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬) 200g을 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10%(w/v) 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 200 g of Compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or Compound 4 (7-hydroxy-6,8-dimethoxychromone) of the present invention was dissolved in 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. A 10% (w / v) gelatin solution was added to the mixture, followed by pulverization and passed through a 14 mesh sieve. This was dried, and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.
제제예 1-2. 주사액제의 제조Formulation Example 1-2. Injection preparation
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬) 1g, 염화나트륨 0.6g 및 아스코르브산 0.1g을 증류수에 용해시켜서 100㎖를 만들었다. 이 용액을 병에 넣고 20℃에서 30분간 가열하여 멸균시켰다.1 g of the present compound (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or compound 4 (7-hydroxy-6,8-dimethoxychromone), 0.6 g of sodium chloride and 0.1 g of ascorbic acid was dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 DEG C for 30 minutes.
<제제예 2. 식품 제조><Formulation Example 2: Food Preparation>
제제예 2-1. 조리용 양념의 제조Formulation Example 2-1. Manufacture of cooking seasonings
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 조리용 양념에 1 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.The compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or the compound 4 (7-hydroxy-6,8-dimethoxychromone) By weight to prepare a cooking sauce for health promotion.
제제예 2-2. 밀가루 식품의 제조Formulation Example 2-2. Manufacture of flour food products
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 밀가루에 0.1 중량%로 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 wt% of Compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or Compound 4 (7-hydroxy-6,8-dimethoxychromone) And the mixture was used to prepare breads, cakes, cookies, crackers and noodles to prepare foods for health promotion.
제제예 2-3. 스프 및 육즙(gravies)의 제조Preparation Example 2-3. Manufacture of soups and gravies
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 스프 및 육즙에 0.1 중량%로 첨가하여 건강 증진용 수프 및 육즙을 제조하였다.The compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or the compound 4 (7-hydroxy-6,8-dimethoxychromone) % ≪ / RTI > by weight to prepare soup for health promotion and juices.
제제예 2-4. 유제품(dairy products)의 제조Formulation Example 2-4. Manufacture of dairy products
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬)를 우유에 0.1 중량%로 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.(7,2'-dihydroxy-6-methoxy-2 S -flavanone) or Compound 4 (7-hydroxy-6,8-dimethoxychromone) of the present invention was added to milk in an amount of 0.1% , And various dairy products such as butter and ice cream were prepared using the milk.
제제예 2-5. 야채주스 제조Formulation Example 2-5. Vegetable juice manufacturing
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬) 0.5g을 토마토주스 또는 당근주스 1,000㎖에 가하여 건강 증진용 야채주스를 제조하였다.0.5 g of Compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or Compound 4 (7-hydroxy-6,8-dimethoxychromone) To 1,000 ml of carrot juice, vegetable juice for health promotion was prepared.
제제예 2-6. 과일주스 제조Formulation Example 2-6. Manufacture of fruit juice
본 발명의 화합물 1(7,2'-디히드록시-6-메톡시-2S-플라바논) 또는 화합물 4(7-히드록시-6,8-디메톡시크로몬) 0.1g을 사과주스 또는 포도주스 1,000㎖에 가하여 건강 증진용 과일주스를 제조하였다.0.1 g of Compound 1 (7,2'-dihydroxy-6-methoxy-2 S -flavanone) or Compound 4 (7-hydroxy-6,8-dimethoxychromone) To 1,000 ml of grape juice, fruit juice for health promotion was prepared.
Claims (6)
[화학식 1]
(Compound 4), 6-methoxychromanone (Compound 5), and 6,7-dimethoxychromone (Compound 6) of the following Formula 1 are selected from the group consisting of 7-hydroxy-6,8-dimethoxychromone Or a pharmaceutically acceptable salt thereof, as an active ingredient.
[Chemical Formula 1]
상기 화합물은 HMGB1(high mobility group box 1)의 발현을 억제하는 효과가 있는 것을 특징으로 하는 혈관 염증 또는 패혈증의 예방 또는 치료용 조성물. The method according to claim 1,
Wherein said compound has an effect of inhibiting the expression of HMGB1 (high mobility group box 1).
[화학식 1]
(Compound 4), 6-methoxychromanone (Compound 5), and 6,7-dimethoxychromone (Compound 6) of the following Formula 1 are selected from the group consisting of 7-hydroxy-6,8-dimethoxychromone Or a pharmaceutically acceptable salt thereof, as an active ingredient.
[Chemical Formula 1]
상기 건강기능식품은 각종 식품류, 음료, 껌, 차 및 비타민 복합제로 이루어진 군에서 선택되는 것을 특징으로 하는 혈관 염증 또는 패혈증의 예방 또는 개선용 건강기능식품.The method of claim 3,
Wherein said health functional food is selected from the group consisting of various foods, beverages, gums, tea and vitamin complex.
[화학식 2]
Extracting Salicornia herbacea with water, C1 to C4 lower alcohol or a mixed solvent thereof to prepare a green tea extract; Sequentially fractionating the green tea extract with hexane and ethyl acetate; And separating 7-hydroxy-6,8-dimethoxychromone (Compound 4) of the following formula (2) by chromatography on each of the above fractions.
(2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170007857A KR101781083B1 (en) | 2017-01-17 | 2017-01-17 | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170007857A KR101781083B1 (en) | 2017-01-17 | 2017-01-17 | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160027905A Division KR101718357B1 (en) | 2016-03-08 | 2016-03-08 | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170104920A KR20170104920A (en) | 2017-09-18 |
KR101781083B1 true KR101781083B1 (en) | 2017-09-22 |
Family
ID=60034526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170007857A KR101781083B1 (en) | 2017-01-17 | 2017-01-17 | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101781083B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023200171A1 (en) * | 2022-04-13 | 2023-10-19 | 전남대학교산학협력단 | Composition including glasswort extract or fraction thereof for prevention, treatment, or alleviation of bone diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200061446A (en) | 2018-11-23 | 2020-06-03 | 김지혜 | Food composition using the salicornia herbacea and method for producing the same |
KR102282946B1 (en) * | 2019-11-04 | 2021-07-27 | 건양대학교 산학협력단 | Composition comprising the extract of Salicornia herbacea L. for preventing, improving or treating inflammation of pregnant women |
-
2017
- 2017-01-17 KR KR1020170007857A patent/KR101781083B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023200171A1 (en) * | 2022-04-13 | 2023-10-19 | 전남대학교산학협력단 | Composition including glasswort extract or fraction thereof for prevention, treatment, or alleviation of bone diseases |
Also Published As
Publication number | Publication date |
---|---|
KR20170104920A (en) | 2017-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2523946B1 (en) | Tricyclic sesquiterpene lactones for used in the treatment of obesity and related diseases and non-therapeutic treatable conditions | |
KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
KR101416149B1 (en) | Composition comprising an extract of Curcuma longa L. or Curcuma aromatica L. isolated therefrom having IL-6 induced STAT3 inhibitory activity | |
KR101781083B1 (en) | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis | |
KR100524373B1 (en) | A pharmaceutical composition containing the extract of saururus chinensis baill useful as an anticancer agent and a process for the preparation thereof | |
KR101718357B1 (en) | Composition comprising compounds isolated from Salicornia herbacea for preventing or treating vascular inflammation or sepsis | |
KR101779391B1 (en) | A composition comprising compounds isolated from Agrimonia pilosa Ledeb. for preventing or treating metabolic disorder | |
KR101585523B1 (en) | Pharmaceutical composition and health functional food for prevention or treatment of cancer comprising compound from dendropanax morbifera lev. extract as effective component | |
KR101754142B1 (en) | Composition comprising quinic acid derivatives for preventing or treating sepsis | |
KR101321879B1 (en) | Hepatoprotective pharmaceutical composition comprising an extract from caryopteris incana and compounds isolated therefrom | |
KR102013398B1 (en) | Composition for preventing or treating cancer comprising codium extracts or fraction thereof, and trail protein | |
KR102075482B1 (en) | A composition for preventing or treating vasculitis comprising lignans from extract of Forsythia koreana flower | |
KR102070721B1 (en) | A pharmaceutical composition comprising compounds isolated from Agrimonia pilosa for preventing or treating cancer | |
KR101338901B1 (en) | Composition comprising extract of Myristica fragrans or lignan compounds isolated therefrom for treating or preventing vascular diseases | |
KR101132174B1 (en) | AMPK activators from Erythrina abyssinica, and compositions for prevention and treatment of metabolic syndromes through activation of AMPK enzyme containing the same as an active ingredients | |
KR101967173B1 (en) | Composition comprising compounds isolated from Morus alba for preventing or treating of inflammatory disease | |
KR101616872B1 (en) | Composition comprising hyperoside for preventing or treating sepsis | |
KR101615891B1 (en) | Composition comprising aspalathin or nothofagin for preventing or treating sepsis | |
KR101848285B1 (en) | Composition comprising rhamnoarabinogalacturonan from mulberry fruit Oddi (Morous alba L.) as active ingredient for preventing or treating of obesity | |
KR102155713B1 (en) | Composition for preventing or treating cancer comprising sea cucumber extracts or fraction thereof, and trail protein | |
KR101454359B1 (en) | Pharmaceutical composition and health functional food for prevention or treatment of cancer comprising compound from dendropanax morbifera lev. extract as effective component | |
KR101466381B1 (en) | Food and pharmaceutical composition for preventing or improving obesitiy comprising specific compound isolated from Eisenia bicyclis as effective component | |
KR100613886B1 (en) | Anti-thrombic activity of ligularia stenocephala m. extract | |
KR102063321B1 (en) | Composition for Preventing or Treating Uterine Myoma Comprising Orostachys japonicus Extract | |
KR101699378B1 (en) | Composition comprising extract of Rhododendron brachycarpum or megastigmane glucosides isolated therefrom for preventing or treating sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |